Navigation Links
Advanced Life Sciences Enters Into Definitive Securities Purchase Agreements for $20 Million with New and Existing Institutional Investors
Date:12/11/2007

CHICAGO, Dec. 11 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation, today announced that it entered into definitive securities purchase agreements dated December 10, 2007, to raise approximately $20 million of gross proceeds through a private placement of approximately 10.2 million shares of common stock and warrants to purchase approximately 5.1 million shares of common stock to a group of new and existing institutional investors. The purchase price for each share of common stock is $1.90 and the warrants are exercisable from the date of grant until the fifth anniversary of such date at an exercise price of $2.15 per share of common stock. The financing is expected to close on or about December 13, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO)

The shares sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States in the absence of an effective registration statement or exemption from applicable registration requirements. The shares were offered and sold only to institutional investors. The Company has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issued in the private placement as well as the shares issuable upon the exercise of the warrants. Lazard Freres & Co. LLC acted as the lead placement agent with Susquehanna Finan
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... Outstanding Issues (LOI) from the European Medicines Agency,s Committee ... NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained release ... being evaluated for weight loss. The key ... adequately addressed by the Company based in part on ...
(Date:7/30/2014)... , July 30, 2014 Researchers often ... interrogate biology, but such devices can do much ... As such, researchers have looked to patterned ... vitro metabolic engineering to characterize – and ... New devices are envisioned to recreate animal and ...
(Date:7/30/2014)... , July 30, 2014  AtheroNova Inc. ... research and development of compounds to safely regress ... today announces that its partner, CardioNova, has accomplished ... clinical trial with AtheroNova,s lead compound, AHRO-001.  This ... the AHRO-001 Phase 1 safety trial completed in ...
(Date:7/30/2014)... NCERC at Southern Illinois University Edwardsville ... on corn stover pretreatment methods at a U.S. ... D.C. , “Arun’s selection for presentation at ... to the success of our postdoctoral fellowship program,” ... foresight and vision of SIUE and the Illinois ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... Jan. 19 /PRNewswire-FirstCall/ - ConjuChem Biotechnologies, Inc. (TSX: CJB) ... independent Board members to explore and evaluate all strategic alternatives ... or the sale of all or a substantial part of ... external consultants to expeditiously make recommendations as to the optimal ...
... Using ... Not Quantity , ... Chicago, IL (PRWeb) January 19, 2010-- Ocean Tomo, LLC, the Chicago-based Intellectual Capital Merchant ... , , , ,The study, which ranks the 25 companies with the Most ...
... , , BIRMINGHAM, Ala. , Jan. ... "bad boy" when it comes to cholesterol. According to a new ... little A" — can be labeled "bad cholesterol." The landmark study ... recently published in the New England Journal Of Medicine ...
Cached Biology Technology:ConjuChem to evaluate strategic alternatives 2Ocean Tomo Study Ranks Top 25 Most Inventive Companies for Bloomberg BusinessWeek, 2Ocean Tomo Study Ranks Top 25 Most Inventive Companies for Bloomberg BusinessWeek, 3Ocean Tomo Study Ranks Top 25 Most Inventive Companies for Bloomberg BusinessWeek, 4New Study: Lp(a) Joins LDL as Heart Disease Risk Factor 2New Study: Lp(a) Joins LDL as Heart Disease Risk Factor 3
(Date:7/30/2014)... as simple as inserting a medicated, disappearing fabric minutes ... have discovered a potentially faster way to deliver a ... method spins the drug into silk-like fibers that quickly ... of the drug than possible with other topical materials ... women a potentially more effective, discreet way to protect ...
(Date:7/30/2014)... colors, nature had already perfected the process think ... example. Now scientists are tapping into those secrets to ... plastics. Their paper on using structure or the ... to produce color appears in the ACS journal ... and colleagues point out that currently, plastic manufacturers add ...
(Date:7/30/2014)... has been awarded the Scientific Committee on Antarctic ... Research. , SCAR, an inter-disciplinary international science body, ... research in the Antarctic region, and on the ... system. The organisation also provides scientific advice about ... governing the region. , The medal is open ...
Breaking Biology News(10 mins):Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... a trait which could be exploited in lands affected by ... the Society for Experimental Biology meeting on July 5, shows ... outer layer of their roots are more efficient at accessing ... Jonathan Lynch at the Pennsylvania State University, United States, found ...
... ITHACA, N.Y. With fewer than a dozen flowering plants ... caloric intake, people need to tap unused plants to feed ... geneticist Susan McCouch in the Comment feature of the July ... with population growth and rising incomes around the world, researchers ...
... TORONTO - A team of Toronto-based researchers may be one ... cells for use in research and therapy. Induced pluripotent ... research because they can flexibly develop into many different types ... proteins that control their generation are largely unknown. But ...
Cached Biology News:To feed the future, we must mine the wealth of the world's seed banks today 2Toronto team ID proteins key in stem cell production 2